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DIAGNOSTIC STUDIES - TREATMENT - DISCUSSION
IgG4 related disease (IgG4-RD) are a rare group of immune mediated disorders with 
heterogeneous clinical presentation but share the same pathologic (lymphoplasmacytic 
infiltration and fibrosis) and serologic (elevated serum IgG4) features. There are only very 
few cases of IgG4-RD associated with lymphomas reported in literature.  
CASE REPORT
A 55-year-old female presented with increasing pressure and discomfort from long 
standing, previously asymptomatic, large, bilateral subcutaneous masses involving 
the upper and lower extremities. She reported multiple excisions in the past with a 
presumable diagnosis of lipomas. Sonography showed soft hypoechoic masses and 
given her history and physical examination, a diagnosis of lipomas was favored. An 
excisional biopsy was performed and the pathology showed a hylanized fibroadipose 
tissue with extensive lymphoid infiltration with associated prominent internodular 
plasmacytic component, occasional atrophic germinal centers and frequent scattered 
eosinophils.  CD138 stain showed numerous plasma cells with almost 100% IgG4 
coexpression.  Additional panel of antibodies demonstrated the plasma cells to be 
kappa-light chain restricted, consistent with a monoclonal plasma cell population and 
a diagnosis of low grade marginal zone B-cell lymphoma (MZL) was rendered.  The 
demonstration of IgG4 in neoplastic plasma cells suggested an underlying IgG4-RD 
with progression to MZL.  
DIAGNOSTIC STUDIES:
A serum electrophoresis was performed showing a faint band that the location was 
indistinct for beta, beta/gamma, or gamma immunoglobin. An immunofixation revealed it 
as an IgG Kappa monoclonal protein. The serum immunoglobin levels were within normal 
limits as were the IgG4 subclass level. A PET CT was performed for further staging of the 
MZL was performed. The results show numerous subcutaneous nodules consistent with 
the know lymphoma, and FGD avid lymph nodes bilaterally in the axilla, pelvis and inguinal 
chains. 
TREATMENT:
The diagnosis is consistent with an IgG4 associated cutaneous MZL. The prognosis for a 
cutaneous MZL is excellent, with the disease usually having an indolent course. The 5-year 
survival is rate has been found to be 98-100%.1,4 A long term retrospective study showed 
a median survival of 47 months, with 5 and 10-year survival at 93%.2 The main stems of 
treatment for this condition are treatment or excision, with both showing a 99% complete 
response rate.4 In this patient after the excision of her lesions, systemic rituximab was 
added as well. In studies a small number of patients have been treated in this way and 
have had a good response; 67% complete remission.3 However, those studies were 
looking at treatment of MZL with rituximab as initial therapy instead of adjuvant as it is 
being used in this case.
DISCUSSION:
There are rare reports of MZL arising from IgG4-RD. IgG4-RD presenting as multiple 
indolent lymphomatous nodules has not been reported in literature. The diagnosis of IgG4-
related disease is currently based on certain histologic criteria and is independent of the 
serologic IgG4 status. The case serves to create awareness about this rare entity and 
emphasize a low threshold to biopsy, which can lead to successful treatments.
This image shows the hylanized fibroadipose tissue with extensive lymphoid 
infiltration.
The tissue in this image was stained for IgG4 which shows the near 100% co-
expression of the immunoglobin.
